Cancer survivorship

Robert S Krouse, Noreen M. Aziz

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Survival from cancer has improved quite dramatically over the past three decades as a result of advances in early detection, adjuvant and other aggressive therapeutic strategies, and the widespread use of combined modality therapy (surgery, chemotherapy, and radiotherapy). Cancers such as testicular, childhood leukemia, and Hodgkin's lymphoma are now considered amenable to cure, patients with common cancers such as breast or colorectal can look forward to a vastly improved disease free and overall survival, and patients with potentially incurable disease can look forward to living for extended periods of time as a result of better disease control (Meadows 1980; Ganz 1998; Schwartz 1999; Aziz 2002; Aziz and Rowland 2003). However, the therapeutic modalities mentioned are associated with a spectrum of late complications ranging from minor and treatable to serious or, occasionally, potentially lethal. One-fourth of late deaths occurring among survivors during the extended survivorship period, when the chances of primary disease recurrence are negligible, can be attributed to a treatment-related effect such as a second cancer or cardiac dysfunction. Most frequently observed sequelae include endocrine complications, growth hormone deficiency, primary hypothyroidism, and primary ovarian failure (Sklar 1999). Also included within the rubric of late effects are second malignant neoplasms arising as a result of genetic predisposition (e.g., familial cancer syndromes) or the mutagenic effects of therapy. These factors may act independently or synergistically. Synergistic effects of mutagenic agents such as cigarette smoke or toxins such as alcohol are largely unknown.

Original languageEnglish (US)
Title of host publicationFundamentals of Cancer Prevention
PublisherSpringer Berlin Heidelberg
Pages363-391
Number of pages29
ISBN (Print)3540242120, 9783540242123
DOIs
StatePublished - 2005

Fingerprint

Survival Rate
Second Primary Neoplasms
Neoplasms
Combined Modality Therapy
Therapeutics
Genetic Predisposition to Disease
Hypothyroidism
Hodgkin Disease
Smoke
Tobacco Products
Growth Hormone
Disease-Free Survival
Survivors
Leukemia
Breast
Radiotherapy
Alcohols
Recurrence
Drug Therapy
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Krouse, R. S., & Aziz, N. M. (2005). Cancer survivorship. In Fundamentals of Cancer Prevention (pp. 363-391). Springer Berlin Heidelberg. https://doi.org/10.1007/3-540-26337-3_16

Cancer survivorship. / Krouse, Robert S; Aziz, Noreen M.

Fundamentals of Cancer Prevention. Springer Berlin Heidelberg, 2005. p. 363-391.

Research output: Chapter in Book/Report/Conference proceedingChapter

Krouse, RS & Aziz, NM 2005, Cancer survivorship. in Fundamentals of Cancer Prevention. Springer Berlin Heidelberg, pp. 363-391. https://doi.org/10.1007/3-540-26337-3_16
Krouse RS, Aziz NM. Cancer survivorship. In Fundamentals of Cancer Prevention. Springer Berlin Heidelberg. 2005. p. 363-391 https://doi.org/10.1007/3-540-26337-3_16
Krouse, Robert S ; Aziz, Noreen M. / Cancer survivorship. Fundamentals of Cancer Prevention. Springer Berlin Heidelberg, 2005. pp. 363-391
@inbook{26d0cf8dda7d4209bea73f6776c3356c,
title = "Cancer survivorship",
abstract = "Survival from cancer has improved quite dramatically over the past three decades as a result of advances in early detection, adjuvant and other aggressive therapeutic strategies, and the widespread use of combined modality therapy (surgery, chemotherapy, and radiotherapy). Cancers such as testicular, childhood leukemia, and Hodgkin's lymphoma are now considered amenable to cure, patients with common cancers such as breast or colorectal can look forward to a vastly improved disease free and overall survival, and patients with potentially incurable disease can look forward to living for extended periods of time as a result of better disease control (Meadows 1980; Ganz 1998; Schwartz 1999; Aziz 2002; Aziz and Rowland 2003). However, the therapeutic modalities mentioned are associated with a spectrum of late complications ranging from minor and treatable to serious or, occasionally, potentially lethal. One-fourth of late deaths occurring among survivors during the extended survivorship period, when the chances of primary disease recurrence are negligible, can be attributed to a treatment-related effect such as a second cancer or cardiac dysfunction. Most frequently observed sequelae include endocrine complications, growth hormone deficiency, primary hypothyroidism, and primary ovarian failure (Sklar 1999). Also included within the rubric of late effects are second malignant neoplasms arising as a result of genetic predisposition (e.g., familial cancer syndromes) or the mutagenic effects of therapy. These factors may act independently or synergistically. Synergistic effects of mutagenic agents such as cigarette smoke or toxins such as alcohol are largely unknown.",
author = "Krouse, {Robert S} and Aziz, {Noreen M.}",
year = "2005",
doi = "10.1007/3-540-26337-3_16",
language = "English (US)",
isbn = "3540242120",
pages = "363--391",
booktitle = "Fundamentals of Cancer Prevention",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Cancer survivorship

AU - Krouse, Robert S

AU - Aziz, Noreen M.

PY - 2005

Y1 - 2005

N2 - Survival from cancer has improved quite dramatically over the past three decades as a result of advances in early detection, adjuvant and other aggressive therapeutic strategies, and the widespread use of combined modality therapy (surgery, chemotherapy, and radiotherapy). Cancers such as testicular, childhood leukemia, and Hodgkin's lymphoma are now considered amenable to cure, patients with common cancers such as breast or colorectal can look forward to a vastly improved disease free and overall survival, and patients with potentially incurable disease can look forward to living for extended periods of time as a result of better disease control (Meadows 1980; Ganz 1998; Schwartz 1999; Aziz 2002; Aziz and Rowland 2003). However, the therapeutic modalities mentioned are associated with a spectrum of late complications ranging from minor and treatable to serious or, occasionally, potentially lethal. One-fourth of late deaths occurring among survivors during the extended survivorship period, when the chances of primary disease recurrence are negligible, can be attributed to a treatment-related effect such as a second cancer or cardiac dysfunction. Most frequently observed sequelae include endocrine complications, growth hormone deficiency, primary hypothyroidism, and primary ovarian failure (Sklar 1999). Also included within the rubric of late effects are second malignant neoplasms arising as a result of genetic predisposition (e.g., familial cancer syndromes) or the mutagenic effects of therapy. These factors may act independently or synergistically. Synergistic effects of mutagenic agents such as cigarette smoke or toxins such as alcohol are largely unknown.

AB - Survival from cancer has improved quite dramatically over the past three decades as a result of advances in early detection, adjuvant and other aggressive therapeutic strategies, and the widespread use of combined modality therapy (surgery, chemotherapy, and radiotherapy). Cancers such as testicular, childhood leukemia, and Hodgkin's lymphoma are now considered amenable to cure, patients with common cancers such as breast or colorectal can look forward to a vastly improved disease free and overall survival, and patients with potentially incurable disease can look forward to living for extended periods of time as a result of better disease control (Meadows 1980; Ganz 1998; Schwartz 1999; Aziz 2002; Aziz and Rowland 2003). However, the therapeutic modalities mentioned are associated with a spectrum of late complications ranging from minor and treatable to serious or, occasionally, potentially lethal. One-fourth of late deaths occurring among survivors during the extended survivorship period, when the chances of primary disease recurrence are negligible, can be attributed to a treatment-related effect such as a second cancer or cardiac dysfunction. Most frequently observed sequelae include endocrine complications, growth hormone deficiency, primary hypothyroidism, and primary ovarian failure (Sklar 1999). Also included within the rubric of late effects are second malignant neoplasms arising as a result of genetic predisposition (e.g., familial cancer syndromes) or the mutagenic effects of therapy. These factors may act independently or synergistically. Synergistic effects of mutagenic agents such as cigarette smoke or toxins such as alcohol are largely unknown.

UR - http://www.scopus.com/inward/record.url?scp=38549114680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549114680&partnerID=8YFLogxK

U2 - 10.1007/3-540-26337-3_16

DO - 10.1007/3-540-26337-3_16

M3 - Chapter

SN - 3540242120

SN - 9783540242123

SP - 363

EP - 391

BT - Fundamentals of Cancer Prevention

PB - Springer Berlin Heidelberg

ER -